Exelixis
EXEL
#1691
Rank
HK$76.59 B
Marketcap
HK$268.20
Share price
-1.71%
Change (1 day)
61.81%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): HK$4.68 Billion

According to Exelixis's latest financial reports the company's current earnings are HK$2.08 Billion. In 2023 the company made an earning of HK$2.00 Billion, an increase over its 2022 earnings that were of HK$1.82 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) HK$4.68 B133.44%
2023 HK$2.00 B9.89%
2022 HK$1.82 B-20.33%
2021 HK$2.29 B124.82%
2020 HK$1.01 B-67.14%
2019 HK$3.09 B-11.94%
2018 HK$3.51 B185.09%
2017 HK$1.23 B-325.82%
2016 -HK$0.55 Billion-58.12%
2015 -HK$1.31 Billion-37.61%
2014 -HK$2.1 Billion9.75%
2013 -HK$1.91 Billion65.96%
2012 -HK$1.15 Billion-291.63%
2011 HK$0.59 B-195.59%
2010 -HK$0.63 Billion-42.17%
2009 -HK$1.09 Billion-18.98%
2008 -HK$1.34 Billion-6.99%
2007 -HK$1.44 Billion46.3%
2006 -HK$0.99 Billion33.25%
2005 -HK$0.74 Billion-30.92%
2004 -HK$1.07 Billion44.29%
2003 -HK$0.75 Billion12.86%
2002 -HK$0.66 Billion22.79%
2001 -HK$0.54 Billion60.14%
2000 -HK$0.34 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
HK$32.47 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$57.67 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
HK$128.37 B 2,648.76%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$53.57 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$36.42 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$143.20 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$9.44 Billion-302.03%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.37 Billion-107.77%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$0.23 Billion-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA